Measured by its ability to inhibit the biological activity of IGF-I or IGF-II on MCF‑7 human breast cancer cells. The IC50 is 8.0-91 ng/mL in the presence of 14 ng/mL human IGF-II.
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | Insulin-like growth factor-binding protein 6, IBP-6, IGF-binding protein 6, IGFBP-6 |
| Accession | P24592 |
| Amino Acid Sequence | Arg28-Gly240, with His at C-terminus |
| Expression System | HEK293 |
| Molecular Weight | 35-40 kDa (Reducing) |
| Endotoxin | <0.1EU/μg |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized Powder |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation |
| Stability & Storage |
·12 months from date of receipt, lyophilized powder stored at -20 to -80℃. ·3 months, -20 to -80℃ under sterile conditions after reconstitution. ·1 week, 2 to 8℃ under sterile conditions after reconstitution. ·Please avoid repeated freeze-thaw cycles. |
Background
Insulin-like Growth Factor Binding Protein-6 (IGFBP-6) is a 30-kDa secreted glycoprotein encoded by the Igfbp6 gene, distinguished by its extraordinary ~50–70-fold binding preference for IGF-II over IGF-I. This selectivity is mediated by cooperative interactions between the N-terminal subdomain and C-terminal domain of IGFBP-6 with adjacent binding sites on IGF-II. IGFBP-6 primarily functions as a selective inhibitor of IGF-II actions, blocking IGF-II-induced cell proliferation, differentiation, migration, and survival across diverse cell types including myoblasts, neuroblastoma cells, and rhabdomyosarcoma cells. Unlike other IGFBPs, it has minimal effect on IGF-I activity.
IGFBP-6 expression is developmentally regulated in mouse skeletal muscle, with high levels during embryogenesis and sustained expression in adult muscle tissue.
Picture
Picture
Bioactivity

SDS-PAGE

2μg (R: reducing condition, N: non-reducing condition).
